TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A MedPage Today opinion article by physician Hamayle Saeed describes being screened for diabetes at a BMI of 23 under Asian-specific guidance but not qualifying for a GLP-1 weight-loss drug at BMI 26.5 without diabetes. The article argues that clinical guidance and insurance rules use different BMI thresholds; how individual insurers apply current drug labels remains unclear.
A South Asian physician says a doctor began diabetes screening at a BMI of 23, but an insurer would not cover a GLP-1 weight-loss drug at BMI 26.5 because she had neither diabetes nor the BMI level commonly used for eligibility. In an October 31 MedPage Today opinion article, Hamayle Saeed, MD, argues that the difference exposes a gap between ethnicity-aware clinical guidance and payer rules.
Saeed writes that the American Diabetes Association’s guidance supports screening Asian American adults for diabetes at lower BMI levels because diabetes risk can arise at lower weights. She says her doctor followed that approach. But she reports that she was denied a GLP-1 receptor agonist because her BMI was below 30 and below 27 with a weight-related condition, and she did not have diabetes. The article does not identify the insurer or provide the denial letter.
The article describes evidence that BMI thresholds may not reflect risk equally across populations. It cites a study of nearly 1.5 million adults in England that compared the BMI at which different ethnic groups reached the diabetes risk associated with a BMI of 30 among white adults. The reported equivalent was 23.9 for South Asian adults and 26.9 for Chinese adults. These findings are population-level comparisons, not individual diagnoses.
Saeed also cites a 2026 analysis of 352 GLP-1 trials, reporting that a BMI eligibility cutoff of 30 would have included 41.5% of non-Asian American adults, 13.5% of Asian Americans and 7.2% of Korean adults. The article says other trial criteria, including measures of blood sugar, kidney function and liver function, admitted more than 93% of each group. These figures describe trial eligibility in the analysis; they do not establish how every insurer makes coverage decisions.
BMI Rules Shape Drug Access
The reported mismatch matters because screening criteria and treatment access criteria serve different purposes, yet both can affect whether a patient receives care. A lower screening threshold can prompt earlier testing without changing a drug’s approved use or guaranteeing insurance coverage. For patients whose risk may be underestimated by a single BMI cutoff, the practical result can be earlier monitoring but continued barriers to medication.
Saeed argues that such barriers may disproportionately affect Asian patients, particularly as some public insurance programs narrow coverage. The article says Medi-Cal ended coverage for GLP-1s for weight loss in January and MassHealth followed in July, but it does not give the policy documents or specify exceptions. The broader policy question is whether clinical evidence about ethnicity and body composition is reflected in prescribing guidance and payer authorization rules.
Access rules also affect what evidence becomes available. If trial enrollment criteria exclude more people from some populations, trial results may be less representative of those groups. That concern does not itself show that a particular patient should receive a medication; individual risks, benefits, and coverage terms still require clinical and payer review.
Products Worth Considering
Withings BPM Connect Smart Blood Pressure Monitor
Withings BPM Vision Blood Pressure Monitor with Wi-Fi and Bluetooth
Withings Body Smart Wi-Fi and Bluetooth Body Composition Scale
As an affiliate, we earn on qualifying purchases.
How Screening and Labels Differ
The World Health Organization set lower BMI action points of 23 and 27.5 for Asian populations in 2004, according to Saeed’s article. The author says the ADA’s 2026 Standards of Care advise clinicians to confirm excess adiposity using cutoffs appropriate to ethnicity and specifically identify South Asian patients. These are clinical recommendations, not automatic insurance benefits.
The article also distinguishes drug labeling from coverage paperwork. Saeed says the 2026 semaglutide (Wegovy) label and the tirzepatide (Zepbound) label describe indications using the terms obesity or overweight with a weight-related condition, without putting a specific BMI number in the indication. She says the familiar thresholds of BMI 30, or 27 with a related condition, persist in trial descriptions and payer prior authorization forms. The article does not reproduce the labels or any specific plan’s criteria, so those details should be checked against current documents.
As another comparison, Saeed says the UK’s National Institute for Health and Care Excellence uses a BMI threshold of 35 with a comorbidity for tirzepatide, while advising a reduction of 2.5 BMI units for several groups, including South Asian and other Asian people. That comparison illustrates differing approaches; it does not establish that UK policy governs US coverage.
“The ADA guideline that flags me for annual diabetes screening and the prior authorization form that denies me the drug are describing the same 26.5.”
— Hamayle Saeed, MD, in a MedPage Today opinion article
Coverage Details Still Need Checking
The account is an opinion article based partly on the author’s own reported experience, not a published investigation into a named insurer’s decision. The source does not identify her health plan, state whether she appealed, or provide the prior authorization criteria applied to her case. It is also unclear how widely plans have updated their rules following the label changes Saeed describes.
The article cites trial analyses and clinical guidance, but those do not settle whether GLP-1 treatment is appropriate for an individual below a given BMI. The source material also does not include full study citations, insurer responses, or comment from drug manufacturers or regulators. Coverage may depend on the specific medicine, diagnosis, plan and policy terms.
Policy Reviews and Patient Appeals
The next practical steps are for patients and clinicians to check the current prescribing information and the exact plan’s authorization policy, including any exceptions, appeal process or alternative coverage route. Saeed’s article does not announce a planned insurer review, government action or change to federal eligibility rules.
Further developments would include whether health plans revise BMI criteria, whether clinical organizations issue more detailed recommendations on treatment thresholds, and whether future trials enroll populations currently underrepresented. Until then, the reported gap remains a policy and access concern rather than confirmation that a specific coverage decision has changed.
Key Questions
What happened in the report?
Physician Hamayle Saeed says she was screened for diabetes at a BMI of 23 but did not qualify for a GLP-1 weight-loss drug at BMI 26.5 without diabetes. She describes the case in an October 31 MedPage Today opinion article.
Why can diabetes screening start below BMI 30?
The article says clinical guidance uses lower BMI thresholds for screening some Asian populations because diabetes risk can occur at lower weights. Screening guidance is not the same as a drug indication or insurance coverage rule.
Does the article say everyone with a BMI of 23 should receive a GLP-1?
No. It argues that population-specific risk and access criteria deserve attention. It does not establish that a particular BMI alone makes GLP-1 treatment appropriate; treatment decisions depend on a person’s health and current prescribing and coverage rules.
Are GLP-1 coverage thresholds changing?
Saeed says current drug labels describe eligibility without a numeric BMI in the indication, while payer forms may still use thresholds such as 30, or 27 with a weight-related condition. The article does not provide plan-by-plan policies, so patients should check their insurer’s current requirements.
Source: medpagetoday.com
